Retinal Hyperspectral Imaging in Neurodegenerative Diseases
Summary
NIH ClinicalTrials.gov registered study NCT07545473 investigating hyperspectral retinal imaging as a non-invasive method for detecting retinal amyloid beta in Alzheimer's disease and other neurodegenerative conditions. The study will enroll participants with or at risk of dementia, including Alzheimer's disease, Parkinson's disease, Lewy-Body dementia, vascular dementia, frontotemporal dementia, and Niemann-Pick diseases. The intervention involves use of a hyperspectral camera to capture retinal image data across multiple wavelengths.
“Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 725 changes logged to date.
What changed
NIH ClinicalTrials.gov registered a clinical study (NCT07545473) on hyperspectral retinal imaging as a non-invasive diagnostic modality for detecting retinal amyloid beta deposits associated with Alzheimer's disease and other neurodegenerative conditions. The study will evaluate participants with diagnosed dementia or at risk of Alzheimer's, and will also assess the technology's potential utility in Parkinson's disease, Lewy-Body dementia, vascular dementia, frontotemporal dementia, and Niemann-Pick diseases. The sole intervention is a hyperspectral camera.
Affected parties include clinical investigators conducting dementia and neurodegenerative disease research, healthcare providers specializing in neurology and geriatric care, and patients enrolled in or considering participation in dementia research programs. The study represents an early-stage diagnostic research protocol and does not establish clinical practice standards or regulatory requirements.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Retinal Hyperspectral Imaging in Neurodegenerative Diseases
N/A NCT07545473 Kind: NA Apr 22, 2026
Abstract
Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides a wealth of information about the retinal structure. Our group has developed evidence supporting a role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. We are undertaking further studies to establish the role of this method in the assessment of people with dementia, or those at risk of Alzheimer's disease. In addition, we wish to test whether the approach may have value in other forms of dementia or neurodegenerative disease such as Parkinson's disease, Lewy-Body dementia or vascular dementia.
Conditions: Dementia, Neurodegenerative Diseases, Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Vascular Dementia, Lewy Body Disease, Niemann-Pick Diseases
Interventions: Hyperspectral camera
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.